HRTIS — Herantis Pharma Oyj Share News
0.000.00%
Last trade - 00:00Brief: Herantis Reports Positive FDA Feedback For HER-096 Study
Brief: Herantis Pharma Partners With Indivi
Brief: Herantis Pharma H2 Loss At EUR 3.4 Mln
Brief: Herantis Pharma Selected For Horizon 2025 Grant
Brief: Herantis Pharma Says Phase 1b Biomarker Data Show Clear Evidence Of Biological Response To HER-096 In Parkinson’s Patients
Brief: Herantis Pharma Announces Successful Completion Of Six-Month Glp Toxicology Study Of Her-096
Brief: Herantis Pharma Says Phase 1B Trial For Parkinson’s Treatment Meets Main, Secondary Goals
Brief: Herantis Pharma Gets Approval Of Clinical Trial Application For Phase 1B Trial
Brief: Herantis Pharma Gets Payment Of EUR 0.75 Mln From European Innovation Council
Brief: Herantis Pharma H2 Result Turns To Profit Of EUR 2.1 Mln
Brief: Herantis Pharma Raises EUR 4.51 Mln Through Directed Share Issue
Brief: Herantis Pharma Announces Positive Topline Data From Clinical Trial
Brief: Herantis Pharma H1 Loss Narrows To EUR 1.8 Mln
Brief: Herantis Pharma H2 Loss For Period Narrows To EUR 3.7 Mln
Brief: Herantis Pharma Announces Approval Of Clinical Trial Application For Phase 1 Study
Brief: Herantis Pharma Selected For European Innovation Council Grant
Brief: Herantis Pharma Applies For Delisting From Nasdaq First North Growth Market Sweden
Brief: Herantis Pharma H1 Loss Narrows To EUR 5.7 Million
Brief: Herantis Pharma: Antti Vuolanto Appointed CEO